Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CACHEXIS oral encapsulated fecal microbiota transplantation study in gastroesophageal cancer cachexia
NL-OMON58327Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) and gastroesophageal junction adenocarcinoma comparing Allogeneic FMT arm with Placebo arm (2 arms). Started Apr 2026; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
cancer anorexia-cachexia syndrome (CACS)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON58327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58327.